Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Eidos Therapeutics closes $64mm Series B round

Executive Summary

Eidos Therapeutics Inc. raised $64mm in a Series B financing round led by RA Capital Management (adds board seat). The company's parent, BridgeBio Pharma, and new investors Janus Henderson, Viking Global Investors, Aisling Capital (adds board seat), Perceptive Advisors, Cormorant Asset Management, and Amzak Health Investors also participated.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies